Opendata, web and dolomites

BITCAT SIGNED

Blocking Inhibition of T-cell Co-stimulation for Anti-tumour Therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BITCAT project word cloud

Explore the words cloud of the BITCAT project. It provides you a very rough idea of what is the project "BITCAT" about.

block    immune    anti    l1    drugs    prolific    advantages    genes    special    cancer    vivo    ctla4    evading    suppression    liposomal    health    good    arose    demonstrated    exon    competitive    nanoparticles    polycationic    researcher    german    antibodies    inhibition    vitro    society    escape    immunity    designed    reduce    toxicity    systemic    propagating    tumours    immunotherapeutics    career    practical    surface    fraunhofer    induce    polyethylenimine    cell    mcmaster    expression    class    ex    immunotherapy    advantageous    oncology    interests    isoforms    checkpoint    renowned    canadian    either    tissue    skipping    completely    antagonistic    tumour    immunology    oligonucleotides    candidates    mechanism    employment    vaccines    bioavailability    rna    genetics    antisense    considerable    world    charmingly    advantage    mediated    university    tested    potentially    protein    area    environment    pd    efficacy    receptor    proper    pto    therapy    clinical    modulate    technique    soluble    scientific    successful    utilized    models   

Project "BITCAT" data sheet

The following table provides information about the project.

Coordinator
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. 

Organization address
address: HANSASTRASSE 27C
city: MUNCHEN
postcode: 80686
website: www.fraunhofer.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 243˙352 €
 EC max contribution 243˙352 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-GF
 Starting year 2017
 Duration (year-month-day) from 2017-05-08   to  2020-05-07

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. DE (MUNCHEN) coordinator 243˙352.00
2    MCMASTER UNIVERSITY CA (HAMILTON) partner 0.00

Map

 Project objective

Tumours escape proper immune response by propagating immune suppression. Immunotherapy aims to enhance anti-tumour immunity. This highly relevant research area arose recently from advantages in immunology, genetics and oncology. Currently, immunotherapeutics are either protein (e.g. antibodies) or cell-based (e.g. cancer vaccines) and promising approaches target immune checkpoint control, a mechanism crucial for anti-tumour T cell activity. Here, development of a completely new class of immunotherapeutics based on advantageous oligonucleotides is proposed. To this aim, oligonucleotides will be designed to modulate expression of receptor genes involved in immune checkpoint control (e.g. PD-L1, CTLA4) and thus block tumour-mediated T cell inhibition. Of special interest will be the employment of the exon skipping technique to reduce surface receptor and potentially induce antagonistic soluble isoforms. To ensure delivery of oligonucleotides, liposomal or polycationic nanoparticles will be utilized as previous studies demonstrated good tissue bioavailability, e.g. for PTO-antisense RNA and polyethylenimine. Oligonucleotides will be tested for functionality, efficacy and non-toxicity in vitro. To facilitate practical clinical application of the developed drugs, most promising candidates will then be applied to pre-clinical tumour models in vivo. Charmingly, this novel technique will also be applied ex vivo to enhance anti-cancer cell therapy, thus evading systemic distribution. Collaboration of two world-renowned scientific institutions, the German Fraunhofer society and Canadian partner McMaster University, will ensure a prolific environment for successful project conclusion and allow considerable advancement of the career of a most promising European researcher. Furthermore, the project will support development of a key technology in the important field of cancer therapy, thus providing a significant competitive advantage for European interests in health research.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BITCAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BITCAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

TOPOCIRCUS (2019)

Simulations of Topological Phases in Superconducting Circuits

Read More  

LipTransProMet (2019)

The multi-omics role of lipid transfer proteins in lipid metabolism

Read More